[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Birmpilis et al., 2019 - Google Patents

Antitumor reactive T-cell responses are enhanced in vivo by DAMP prothymosin alpha and its C-terminal decapeptide

Birmpilis et al., 2019

View HTML
Document ID
12584092202431791877
Author
Birmpilis A
Karachaliou C
Samara P
Ioannou K
Selemenakis P
Kostopoulos I
Kavrochorianou N
Kalbacher H
Livaniou E
Haralambous S
Kotsinas A
Farzaneh F
Trougakos I
Voelter W
Dimopoulos M
Bamias A
Tsitsilonis O
Publication year
Publication venue
Cancers

External Links

Snippet

Prothymosin α (proTα) and its C-terminal decapeptide proTα (100–109) were shown to pleiotropically enhance innate and adaptive immune responses. Their activities have been broadly studied in vitro, focusing primarily on the restoration of the deficient immunoreactivity …
Continue reading at www.mdpi.com (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6012—Haptens, e.g. di- or trinitrophenyl (DNP, TNP)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Similar Documents

Publication Publication Date Title
Jiang et al. BCG in bladder cancer immunotherapy
Srivastava et al. A characterization of dendritic cells and their role in immunotherapy in glioblastoma: from preclinical studies to clinical trials
Lurje et al. Dendritic cell and T cell crosstalk in liver fibrogenesis and hepatocarcinogenesis: implications for prevention and therapy of liver cancer
Kciuk et al. Recent advances in molecular mechanisms of cancer immunotherapy
Koucký et al. Immunology of plasmacytoid dendritic cells in solid tumors: a brief review
Del Prete et al. Functional role of dendritic cell subsets in cancer progression and clinical implications
Fu et al. Plasmacytoid dendritic cells and cancer immunotherapy
Matsuo et al. Recent progress in dendritic cell-based cancer immunotherapy
Jie et al. CpG ODN1826 as a promising mucin1-maltose-binding protein vaccine adjuvant induced DC maturation and enhanced antitumor immunity
Caisova et al. The significant reduction or complete eradication of subcutaneous and metastatic lesions in a pheochromocytoma mouse model after immunotherapy using mannan-BAM, TLR ligands, and anti-CD40
Komorowski et al. Modulation of the tumor microenvironment by CXCR4 antagonist-armed viral oncotherapy enhances the antitumor efficacy of dendritic cell vaccines against neuroblastoma in syngeneic mice
Hernández et al. Plasmacytoid dendritic cells as a novel cell-based cancer immunotherapy
Kim et al. Comparison of exosomes derived from non-and gamma-irradiated melanoma cancer cells as a potential antigenic and immunogenic source for dendritic cell-based immunotherapeutic vaccine
Terbuch et al. Next generation cancer vaccines—make it personal!
Wandmacher et al. Challenges and future perspectives of immunotherapy in pancreatic cancer
Bhatnagar et al. Combination of STING and TLR 7/8 agonists as vaccine adjuvants for cancer immunotherapy
Guo et al. Fusion protein vaccine based on Ag85B and STEAP1 induces a protective immune response against prostate cancer
Lin et al. Breast cancer tumor microenvironment and molecular aberrations hijack tumoricidal immunity
Ornella et al. Immunotherapy for peritoneal carcinomatosis: challenges and prospective outcomes
Murgaski et al. Unleashing tumour-dendritic cells to fight cancer by tackling their three A’s: abundance, activation and antigen-delivery
Wang et al. Intranasal administration of Codium fragile polysaccharide elicits anti-cancer immunity against Lewis lung carcinoma
Song et al. Bombyx batryticatus protein-rich extract induces maturation of dendritic cells and Th1 polarization: a potential immunological adjuvant for cancer vaccine
Zhang et al. Breast cancer vaccine containing a novel toll-like receptor 7 agonist and an aluminum adjuvant exerts antitumor effects
Kim et al. Annona muricata L.-derived polysaccharides as a potential adjuvant to a dendritic cell-based vaccine in a thymoma-bearing model
Nahar et al. Regression and eradication of triple-negative breast carcinoma in 4T1 mouse model by combination immunotherapies